Examkin

Question

Difficulty: MediumPreventive Care and Immunizations

A 12-month-old boy is brought to the clinic for a routine well-child visit. Three months ago, he was hospitalized for prolonged fever, bilateral nonexudative conjunctivitis, oral mucosal changes, and a polymorphous rash. He was diagnosed with Kawasaki disease and successfully treated with a single dose of intravenous immunoglobulin (IVIG) and high-dose aspirin. He is currently asymptomatic, his recent echocardiograms have been normal, and he takes low-dose aspirin daily. Physical examination today reveals a healthy, active infant. His growth parameters are at the 50th percentile. He received all recommended immunizations up to his 6-month visit. According to current guidelines, which of the following is the most appropriate immunization plan for this patient today?

  1. Administer pneumococcal conjugate, Haemophilus influenzae type b, and hepatitis A vaccines; defer MMR and varicella vaccines.Answer
  2. B
    Administer all age-appropriate vaccines, including MMR and varicella vaccines.
  3. C
    Administer pneumococcal conjugate, Haemophilus influenzae type b, hepatitis A, and MMR vaccines; defer the varicella vaccine.
  4. D
    Administer MMR and varicella vaccines; defer pneumococcal conjugate, Haemophilus influenzae type b, and hepatitis A vaccines.
  5. E
    Defer all immunizations today and schedule a return visit in 8 months.

Answer

The correct plan is to administer inactivated vaccines (pneumococcal conjugate, Haemophilus influenzae type b, and hepatitis A) and defer live-attenuated vaccines (MMR and varicella).
The correct plan administers inactivated vaccines and defers live vaccines. A 12-month-old infant is normally due for both inactivated vaccines (PCV, Hib, HepA) and live-attenuated vaccines (MMR, Varicella). However, this patient received high-dose intravenous immunoglobulin (IVIG) 3 months ago for Kawasaki disease. IVIG contains a concentrated pool of exogenous IgG antibodies that will bind to and neutralize live-attenuated viral vaccines, rendering them ineffective. Therefore, live vaccines must be deferred (an 11-month delay is required following the high doses of IVIG used for Kawasaki disease). Because inactivated vaccines do not require viral replication to induce an immune response, they are completely unaffected by circulating exogenous antibodies and must be administered on their normal schedule to ensure continuous protection.

Step-by-Step Solution

1
Identify the standard vaccines indicated at a 12-month well-child visit.
The standard schedule includes both inactivated vaccines (PCV, Hib, HepA) and live-attenuated vaccines (MMR, Varicella).
Establishing the baseline vaccine requirements is the first step in well-child care.
2
Evaluate the impact of the patient's past medical history on the vaccination schedule.
The patient received high-dose IVIG for Kawasaki disease 3 months ago.
Medical treatments, particularly blood products, can alter immunization protocols.
3
Apply the rules for vaccine administration following IVIG therapy.
Live-attenuated vaccines must be deferred for 11 months post-IVIG, while inactivated vaccines can be given safely on schedule.
Exogenous antibodies in IVIG neutralize live vaccine viruses but do not affect the immune response to inactivated antigens.

Key Concept

Administration of antibody-containing products like IVIG necessitates a delay in giving live-attenuated viral vaccines (e.g., MMR, Varicella) because passive antibodies interfere with the active immune response. Inactivated vaccines are not affected and should be given on schedule.
Rate this question

Topics

Preventive Care and Immunizations

More questions from this topic